Incyte (NASDAQ:INCY) Given New $92.00 Price Target at Royal Bank Of Canada

Incyte (NASDAQ:INCY) had its target price cut by Royal Bank Of Canada from $95.00 to $92.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on INCY. Weiss Ratings reiterated a “hold (c+)” rating on shares of Incyte in a research note on Thursday, January 22nd. Guggenheim upgraded Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price objective for the company in a research note on Monday, November 3rd. The Goldman Sachs Group reiterated a “neutral” rating and set a $90.00 target price on shares of Incyte in a research note on Thursday, January 8th. Barclays increased their price target on shares of Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Finally, Piper Sandler lifted their price objective on shares of Incyte from $102.00 to $110.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $103.94.

Incyte Price Performance

Shares of NASDAQ INCY traded up $1.30 during midday trading on Wednesday, reaching $100.14. The company’s stock had a trading volume of 298,870 shares, compared to its average volume of 2,070,212. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.23. The company has a market cap of $19.66 billion, a P/E ratio of 15.61, a P/E/G ratio of 0.60 and a beta of 0.82. The business’s 50 day moving average price is $101.75 and its two-hundred day moving average price is $93.81. Incyte has a fifty-two week low of $53.56 and a fifty-two week high of $112.29.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.Incyte’s revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the business earned $1.43 EPS. On average, analysts forecast that Incyte will post 4.86 EPS for the current fiscal year.

Insider Transactions at Incyte

In other Incyte news, EVP Steven H. Stein sold 20,105 shares of Incyte stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the completion of the sale, the executive vice president owned 63,129 shares of the company’s stock, valued at $6,471,353.79. The trade was a 24.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael James Morrissey sold 54,008 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $97.29, for a total value of $5,254,438.32. Following the sale, the executive vice president owned 31,830 shares of the company’s stock, valued at $3,096,740.70. This represents a 62.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 95,225 shares of company stock worth $9,519,745 in the last three months. Insiders own 17.80% of the company’s stock.

Institutional Investors Weigh In On Incyte

Several hedge funds have recently bought and sold shares of the business. Elyxium Wealth LLC bought a new position in shares of Incyte during the fourth quarter valued at approximately $28,000. Smithfield Trust Co increased its position in Incyte by 135.0% during the 4th quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 162 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new position in Incyte during the third quarter valued at $26,000. Root Financial Partners LLC bought a new stake in Incyte in the third quarter worth $28,000. Finally, Quent Capital LLC purchased a new stake in shares of Incyte in the third quarter worth $30,000. Institutional investors own 96.97% of the company’s stock.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Revenue beat and product sales strength: Q4 revenue of $1.51B topped estimates and product sales (Jakafi, Opzelura) drove a ~28% revenue increase year-over-year, supporting near-term cash generation and validating commercial traction. INCY Q4 revenue beat
• Positive Sentiment: Pipeline and 2026 top-line growth plan: Management outlined a 10–13% revenue growth target for 2026 and highlighted pipeline expansion and new launches (supporting longer-term upside if successful). 2026 revenue growth outline
• Positive Sentiment: Non-core asset sale improves balance-sheet optionality: Incyte sold Wilmington Bracebridge towers to BPG, a small but constructive liquidity/asset-mgmt move. Property sale
• Neutral Sentiment: Mixed analyst landscape: Firms trimmed price targets and ratings (RBC, Wells Fargo) while HC Wainwright reiterated a Buy with a $135 target — creating divergent near-term sentiment among institutional holders. HC Wainwright buy rating
• Negative Sentiment: EPS miss and conservative near‑term guidance hurt sentiment: Q4 EPS missed estimates ($1.80 vs. $1.96) and management gave a softer net-product revenue guide, prompting a gap-down and investor concern about short-term growth trajectory. Shares gap down after earnings miss
• Negative Sentiment: Opzelura guidance and Jakafi LOE concerns: Investors noted light Opzelura guidance and the approaching loss of exclusivity for Jakafi, which increases revenue risk if pipeline replacements underperform. Jakafi LOE and Opzelura
• Negative Sentiment: Regulatory pricing risk: New U.S. pricing policy proposals (so-called “most favored nation” approaches) were flagged as an emerging regulatory risk that could pressure future revenues and margins. Drug pricing policy risk

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.